Frequent inactivation of SPARC by promoter hypermethylation in colon cancers
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Epigenetic modification of gene expression plays an important role in the development of human cancers. The inactivation of SPARC through CpG island methylation was studied in colon cancers using oligonucleotide microarray analysis and methylation specific PCR (MSP). Gene expression of 7 colon cancer cell lines was evaluated before and after treatment with the demethylating agent 5‐aza‐2′‐deoxycytidine (5Aza‐dC) by oligonucleotide microarray analysis. Expression of SPARC was further examined in colon cancer cell lines and primary colorectal cancers, and the methylation status of the SPARC promoter was determined by MSP. SPARC expression was undetectable in 5 of 7 (71%) colorectal cancer cell lines. Induction of SPARC was demonstrated after treatment with the demethylating agent 5Aza‐dC in 5 of the 7 cell lines. We examined the methylation status of the CpG island of SPARC in 7 colon cancer cell lines and in 20 test set of colon cancer tissues. MSP demonstrated hypermethylation of the CpG island of SPARC in 6 of 7 cell lines and in all 20 primary colon cancers, when compared with only 3 of 20 normal colon mucosa. Immunohistochemical analysis showed that SPARC expression was downregulated or absent in 17 of 20 colon cancers. A survival analysis of 292 validation set of colorectal carcinoma patients revealed a poorer prognosis for patients lacking SPARC expression than for patients with normal SPARC expression (56.79% vs. 75.83% 5‐year survival rate, p = 0.0014). The results indicate that epigenetic gene silencing of SPARC is frequent in colon cancers, and that inactivation of SPARC is related to rapid progression of colon cancers. © 2007 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Cited by
Aoi, W., Naito, Y., Takagi, T., Tanimura, Y., Takanami, Y., Kawai, Y., Sakuma, K., Hang, L. P., Mizushima, K., Hirai, Y., et al. (2013) · Gut · doi:10.1136/gutjnl-2011-300776 · Cited by 347
“In addition, cycloheximide but not actinomycin D inhibited the secretion of SPARC.”
InfluentialDNA methylation markers in colorectal cancer
Kim, M. S., Lee, J., & Sidransky, D. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9207-6 · Cited by 303
Desai, N. P., Trieu, V., Hwang, L. Y., Wu, R., Soon-Shiong, P., & Gradishar, W. J. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32830f9046 · Cited by 205
SPARC: a matricellular regulator of tumorigenesis
Arnold, S. A., & Brekken, R. A. (2009) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-009-0072-4 · Cited by 182
“This paradoxical pattern of SPARC expression is observed in breast, colorectal, lung, ovarian, pancreatic and endometrial cancers (Barth et al. 2005; Iacobuzio-Donahue et al. 2002; Paley et al. 2000; Rodriguez-Jimenez et al. 2007; Sato et al. 2003; Suzuki et al. 2005; Yang et al. 2007; Yiu et al. 2001).”
BackgroundMethodInfluentialChan, S. K., Griffith, O. L., Tai, I. T., & Jones, S. J. M. (2008) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-2615 · Cited by 159
“However, another immunohistochemistry study (39) showed down-regulation of SPARC due to methylation of its promoter.”
BackgroundInfluentialArnold, S. A., Rivera, L. B., Miller, A. F., Carbon, J. G., Dineen, S. P., Xie, Y., Castrillon, D. H., Sage, E. H., Puolakkainen, P., Bradshaw, A. D., et al. (2010) · Disease Models & Mechanisms · doi:10.1242/dmm.003228 · Cited by 118
Mukherjee, S., Choi, M. J., Kim, S. W., & Yun, J. W. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.110757 · Cited by 24
Metadata
- Authors
- Yang, E., Kang, H. J., Koh, K. H., Rhee, H., Kim, N. K., & Kim, H.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2007-05-25
- Volume
- 121
- Issue
- 3
- Pages
- 567-575
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2055679227
- Cited by
- 129
- References
- 1
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.